Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebocontrolled, randomised PSUMMIT 2 trial

Annals of the Rheumatic Diseases

Volumn 73, Issue 6, 2014, Pages 990-999

  Ritchlin, Christopher ^a   Rahman, Proton ^b   Kavanaugh, Arthur ^c   McInnes, Iain B ^d   Puig, Lluis ^e   Li, Shu ^f   Wang, Yuhua ^f   Shen, Yaung Kaung ^f   Doyle, Mittie K ^g   Mendelsohn, Alan M ^f   Gottlieb, Alice B ^h  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^f JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^g ALEXION PHARMACEUTICALS   (United States)

^h TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 23 ANTIBODY; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB;

ACUTE KIDNEY FAILURE; ADULT; ARTHRALGIA; ARTICLE; BACKACHE; BACTEREMIA; BODY WEIGHT; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DACTYLITIS; DEHYDRATION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ENTHESITIS; FAINTNESS; FATIGUE; FEMALE; FUNCTIONAL STATUS; HEADACHE; HEALTH ASSESSMENT QUESTIONNAIRE; HEART INFARCTION; HUMAN; INFECTION; INVASIVE CANDIDIASIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OROPHARYNX PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SEPTIC SHOCK; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION;

ANTI-TNF; PSORIATIC ARTHRITIS; SPONDYLOARTHRITIS;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; INTERLEUKIN-12 SUBUNIT P40; MALE; METHOTREXATE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84899991797     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204655     Document Type: Article

References (40)

1. Gladman D, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64(Suppl II):ii14-17. (Pubitemid 40288513)
2. Ritchlin CT. From skin to bone: translational perspectives on psoriatic disease. J Rheumatol 2008;35: 1434-7. (Pubitemid 352000800)
3. Torre Alonso JC, Rodriguez Perez A, Arribas Castrillo JM, et al. Psoriatic arthritis (PsA): a clinical, immunological and radiological study of 180 Patients. Br J Rheumatol 1991;30: 245-50.
4. Sokoll KB, Helliwell PS. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol 2001;28: 1842-6. (Pubitemid 32726931)
5. Wong K, Gladman DD, Husted J, et al. Mortality studies in psoriatic arthritis. Results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 1997;40: 1868-72. (Pubitemid 27452539)
6. Gladman DD, Farewell VT, Wong K, et al. Mortality studies in psoriatic arthritis. Results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 1998;41: 1103-10. (Pubitemid 28265412)
7. Khraishi M, MacDonald D, Rampakakis E, et al. Prevalence of patient-reported comorbidities in early and established psoriatic arthritis cohorts. Clin Rheumatol 2011;30: 877-85.
8. Raychaudhuri SP. Comorbidities of psoriatic arthritis-metabolic syndrome and prevention: a report from the GRAPPA 2010 Annual Meeting. J Rheumatol 2012;39: 437-40.
9. Tenga G, Goëb V, Lequerré T, et al. A 3 mg/kg starting dose of infliximab in active spondyloarthritis resistant to conventional treatments is efficient, safe and lowers costs. Joint Bone Spine 2011;78: 50-5.
10. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo controlled trial (PHOENIX 1). Lancet 2008;371: 1665-74. (Pubitemid 351671883)
11. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo controlled trial (PHOENIX 2). Lancet 2008;371: 1675-84. (Pubitemid 351671884)
12. Griffiths CE, Strober BE, van de Kerkhof P, et al. on behalf of the ACCEPT Study Group. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010;362: 118-28.
13. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009;373: 633-40.
14. McInnes IB, Kavanaugh A, Gottlieb AB, et al. on behalf of the PSUMMIT I Study Group. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1-year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT I trial. Lancet 2013;382: 780-9.
15. Taylor W, Gladman D, Helliwell P, et al. for the CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54: 2665-73. (Pubitemid 44205029)
16. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology: preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38: 727-35.
17. Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38: 44-8.
18. van Riel PL, van Gestel AM, Scott DL. EULAR handbook of clinical assessments in rheumatoid arthritis. Alphen Aan Den Rijn, The Netherlands: Van Zuiden Communications, 2000.
19. Aletaha D, Landewe R, Karonitsch T, et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis 2008;67: 1360-4.
20. Wells G, Becker JC, Teng J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009;68: 954-60.
21. Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978;157: 238-44. (Pubitemid 8387357)
22. Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23: 137-45. (Pubitemid 10164318)
23. Mease PJ, Ganguly R, Wanke L, et al. How much improvement in functional status is considered important by patients with active psoriatic arthritis: applying the outcome measures in rheumatoid arthritis clinical trials (OMERACT) group guidelines. Ann Rheum Dis 2004;63(Suppl 1):391.
24. Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003;62: 127-32. (Pubitemid 36135387)
25. Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21: 2286-91.
26. Zochling J, van der Heijde D, Burgos-Vargas R, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006;65: 442-52.
27. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): conceptual framework and item selection. Med Care 1992;30: 473-83.
28. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19: 210-16. (Pubitemid 24194579)
29. Cella D, Yount S, Sorensen M, et al. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol 2005;32: 811-19. (Pubitemid 40676488)
30. Conover WJ. Practical nonparametric statistics. 2nd edn. New York: John Wiley & Sons, Inc., 1999: 318-20.
31. Kavanaugh A, Ritchlin C, Rahman P, et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicenter, randomized, double-blind, placebo-controlled PSUMMIT 1 and PSUMMIT 2 trials. Ann Rheum Dis 2014;73: 1000-6.
32. Buch MH, Rubbert-Roth A, Ferraccioli G. To switch or not to switch after a poor response to a TNFα blocker? It is not only a matter of ACR20 OR ACR50. Autoimmun Rev 2012;11: 558-62.
33. Ruiz Salas V, Puig L, Alomar A. Ustekinumab in clinical practice: response depends on dose and previous treatment. J Eur Acad Dermatol Venereol 2012;26: 508-13.
34. Fagerli KM, Lie E, van der Heijde D, et al. Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study. Ann Rheum Dis 2013;72: 1840-4.
35. Glintborg B, Ostergaard M, Krogh NS, et al. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO Registry. Arthritis Rheum 2013;65: 1213-23.
36. Laws PM, Downs AM, Parslew R, et al. Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland. Br J Dermatol 2012;166: 189-95.
37. Fénix-Caballero S, Alegre-del Rey EJ, Castaño-Lara R, et al. Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis. J Clin Pharm Ther 2013;38: 286-93.
38. McInnes IB, Papp K, Puig L, et al. Safety of ustekinumab from the placebo-controlled periods of psoriatic arthritis and psoriasis clinical development programs. Arthritis Rheum 2013;65(Suppl):S138-9. Abstract 323.
39. Lebwohl M, Leonardi C, Griffiths CE, et al. Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. J Am Acad Dermatol 2012;66: 731-41.
40. Papp KA, Griffiths CE, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol 2013;168: 844-54.